AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02285751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel
Study NCT02285751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel
Study NCT02285751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Study NCT01989533 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ad4-mgag
Description: Ad4 live virus vaccine with an HIV insert
Study NCT01989533 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad4-mgag
Description: Ad4 live virus vaccine with an HIV insert
Study NCT01989533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-mgag
Description: Ad4 live virus vaccine with an HIV insert
Study NCT01989533 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ad4-EnvC150
Description: Ad4 live virus vaccine with an HIV insert
Study NCT01989533 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad4-EnvC150
Description: Ad4 live virus vaccine with an HIV insert
Study NCT01989533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-EnvC150
Description: Ad4 live virus vaccine with an HIV insert
Study NCT01989533 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: gp 120 Protein Boost
Description: HIV protein boost
Study NCT01989533 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: gp 120 Protein Boost
Description: HIV protein boost
Study NCT01989533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp 120 Protein Boost
Description: HIV protein boost
Study NCT01175694 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Interstitial multicatheter brachytherapy
Description: Interstitial PDR- and HDR-brachytherapy up to 50 Gy-eq
Study NCT05589545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis
Description: A prosthetic full-arch rehabilitation of atrophic maxillae using a PEEk-acrylic resin prosthesis supported by an ensemble of standard dental implants and zygomatic dental implants, following the All-on-4 Hybrid Concept.
Study NCT03899116 — intervention group
Intervention type: OTHER
Intervention: deflation of pneumatic tourniquet
Description: gradual deflation with variable degrees
Study NCT00192179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza vaccine trivalent (CAIV-T)
Description: The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 ml into each nostril). Each dose of CAIV-T used in this study contained approximately 10\^7+/-0.5 fluorescent focus units (FFU) (equivalent to 10\^7+/-0.5 TCID50) of each of the following three influenza virus strains: Influenza Cold Adapted Virus Type H1N1, strain A/New Caledonia/20/99; Influenza Cold Adapted Virus Type H3N2, strain A/ Panama/2007/99; Influenza Cold Adapted Virus Type B, strain B/Hong Kong/ 330/01.
Study NCT00192179 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consisted of physiologic normal saline.
Study NCT05571501 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gait assessment using the GAITRIte walkway
Description: 10-20 walking assessment using the GAITRite walkway
Study NCT03980847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate 20 mg
Description: The Alendronate 20 mg combined with nanocrystalline hydroxyapatite as a synthetic bone substitute for socket preservation after tooth extraction
Study NCT03980847 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nanocrystal hydroxyapatite
Description: Postextraction Sockets Preserved With Nanocrystal hydroxyapatite as a synthetic bone substitute alone as a bone graft
Study NCT02565797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DabirAIR alternating pressure overlay
Description: DabirAIR alternating pressure overlay is a dynamic support surface that is placed on top a mattress. The DabirAIR overlay provides periodic pressure relief through the alternate inflation and deflation of air cells.
Study NCT00844545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange
Study NCT02558608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DIPL
Description: dissection of the inferior pulmonary ligament
Study NCT02558608 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: WR
Description: wedge resection of the lung bleb
Study NCT02558608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WR
Description: wedge resection of the lung bleb
Study NCT02558608 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracoscopic surgery
Description: surgery performed by video assisted thoracoscopy
Study NCT02558608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracoscopic surgery
Description: surgery performed by video assisted thoracoscopy
Study NCT00537056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium-DTPA
Description: 0.1 mmol/kg iv
Study NCT00537056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50 mg/day po
Study NCT01019681 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord blood stem cell injection
Description: The cord blood stem cells will be simply injected intramuscularly in the leg. 30 minutes prior to stem cell injection the patients will receive Vancomycin 1 gram IVPB x1 as a prophylactic measure. Patients will also receive Ativan 0.5 to 1 mg PO x 1 and Dilaudid 0.5 to 1 mg IV x1 to alleviate the discomfort of the procedure.~Cells will be injected by means of a 22 gauge sterile spinal needle after topical anesthesia of the injection site. The concentration will be at least 2 x 107 total nucleated cells per ml in phosphate buffered saline (PBS) with 5% human serum albumin (Baxter, Deerfield Illinois).
Study NCT01532687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT01532687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV
Study NCT01532687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT03911882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Celergen Administration
Description: The food supplement Celergen was administered on a daily basis for a total of 3 months (90 days) to participating fibromyalgia patients
Study NCT01854125 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous bone marrow mesenchymal stem cells transplantation
Description: Autologous MSCs were infused to patients using interventional method via hepatic artery . The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes.
Study NCT01854125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous bone marrow mesenchymal stem cells transplantation
Description: Autologous MSCs were infused to patients using interventional method via hepatic artery . The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes.
Study NCT01854125 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous bone marrow msenchymal stem cells transplantation
Study NCT01854125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous bone marrow msenchymal stem cells transplantation
Study NCT01532687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT01532687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04070534 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PALS
Description: patient activated learning system
Study NCT04437407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PB2-1 prototype
Description: PB2-1 prototype is a belt-like wearable device similar to the original PrenaBelt designed for pregnant women that permits supine positioning of the pelvis but, when in this position, provides subtle pressure points to the user's body and thereby activates the body's natural mechanism to reposition itself to relieve discomfort. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
Study NCT04437407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PB2-2 prototype
Description: PB2-2 prototype is a belt-like wearable device designed for pregnant women. When placed on the woman's back, this device prevents the pelvis from achieving a supine orientation by maintaining at least fifteen degrees of right or left lateral pelvic tilt. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
Study NCT04437407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PB2-3 prototype
Description: PB2-3 prototype is a belt-like wearable device designed for pregnant women. When placed on the woman's back, this device prevents the pelvis from achieving a supine orientation by maintaining at least fifteen degrees of right or left lateral pelvic tilt. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
Study NCT04437407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PB2-4 prototype
Description: PB2-4 prototype is a belt-like wearable device designed for pregnant women that prevents the user from achieving a supine position as the device allows right and left lateral pelvic tilt but prevents the user's pelvis from settling supine due to virtue of its design. It is expected to significantly decrease the amount of time a pregnant woman's pelvis is in the supine position overnight while promoting comfortable sleep.
Study NCT04437407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PB2-5 prototype
Description: PB2-5 prototype is a belt-like wearable device designed for pregnant women that does not provide positional therapy. It can be worn anytime as a maternity support belt.
Study NCT04437407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ajuvia-Active
Description: Ajuvia Sleep Monitor senses the user's body position and can be used in passive or active mode with or without the PB2 prototypes. In the active mode, it alerts the woman when her pelvis is in the supine position through a gentle vibratory alarm.
Study NCT04437407 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ajuvia-Passive
Description: Ajuvia Sleep Monitor senses the user's body position and can be used in passive or active mode with or without the PB2 prototypes. In the passive mode, it measures and records the position of the pelvis but does not alert the woman.
Study NCT04437407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ajuvia-Passive
Description: Ajuvia Sleep Monitor senses the user's body position and can be used in passive or active mode with or without the PB2 prototypes. In the passive mode, it measures and records the position of the pelvis but does not alert the woman.
Study NCT00896038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant is a neurokinin 1 receptor antagonist shown to have anti-stress actions in preclinical studies, and antidepressant efficacy in human clinical trials
Study NCT00896038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active placebo
Study NCT01019109 — intervention group
Intervention type: DEVICE
Intervention: Posterior Spinal Fusion Device: Titanium rod arm used titanium rods, and CoCr rod arm used Cobalt Chrome rods as a part of the construct.
Description: PASS LP Implant System is designed to contribute to correction and surgical stabilization of the thoracic, lumbar and sacral spine only. These implants are designed to stabilize the spine during normal development of solid bony consolidation which takes about 18 months. The internal fixation devices are composed of screws, hooks,rods, plates, cross links, connection and locking devices. The range of different sizes and shapes of the implants allows the surgeon to adapt to the pathology and morphology of each of his patients.
Study NCT01532687 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01532687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Given PO
Study NCT01532687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Description: Given PO
Study NCT01532687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study NCT01532687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study NCT01532687 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT00807092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: The initial doses for BIAsp 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 U/kg body weight and to be equally divided (1/2:1/2) between pre-breakfast and pre-dinner
Study NCT00807092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic human insulin 30
Description: The initial doses for BHI 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 IU/kg body weight and to be divided in the ratio of 2/3:1/3 between pre-breakfast and pre-dinner
Study NCT00807092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Metformin dose must remain the same as that used prior to the trial.
Study NCT03844191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RUC-4 Compound
Description: single subcutaneous administration of RUC-4
Study NCT01788540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid
Description: IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.the intralipid infusion is then repeated within the 1st week of positive pregnancy test and every 2 weeks till end of first trimester
Study NCT01114841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene Foam
Description: Patches containing Tazarotene Foam 0.1% will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.~There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).~These patches will then be evaluated at 24, 48, and 72 hours.~There may be a second rest period and a second 48-hour patch application and evaluation, if required.
Study NCT01114841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Patches containing Vehicle Foam will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.~There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).~These patches will then be evaluated at 24, 48, and 72 hours.~There may be a second rest period and a second 48-hour patch application and evaluation, if required.
Study NCT02483247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503
Description: Patients in this trial will receive BBI503 orally, daily, and continuously. The dose-level of BBI503 will be assigned according to the dose-cohort open at the time the patient enrolls into a given arm. The study-arm and combination anti-cancer agent for a given patient will be determined by the investigator. BBI503 Dose Level 1: 200 mg once daily, Dose Level 2: 300 mg once daily.
Study NCT04476459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab will be administered every 3 weeks up to 6 cycles during induction phase, and then every 4 weeks up to 12 cycles in maintenance phase if patients get CR or PR after induction phase.
Study NCT04476459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Phase I: dose escalation phase. Patients will oral dosage as 250mg, 500mg or 750mg,qd, per day. Aim to evaluate MTD and DLT, RP2D.~Phase II：Patients continuous oral apatinib as RP2D up to 6 cycles during induction phase, and then 250mg/d up to 1 year in maintenance phase if patients get CR or PR after induction phase.
Study NCT02483247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m\^2 body surface area is administered orally, twice daily, on days 1-14 of each 21 day cycle.
Study NCT02483247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 60 mg/m\^2 body surface area is administered intravenously once every three weeks (21-days).
Study NCT02483247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes on day 1 and day 15 of each 28 day cycle.
Study NCT02483247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every three weeks (21-days).
Study NCT02483247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m\^2 body surface area is administered intravenously once weekly on day 1, day 8, and day 15 of each 28 day cycle.
Study NCT02483247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 37.5 mg is administered once daily.
Study NCT04488276 — intervention group
Intervention type: OTHER
Intervention: In-depth interviews
Description: In-depth interviews will be conducted to understand how smoking partners of pregnant women perceive risks and behaviors related to SHS exposure and how can it be altered to decrease exposure of pregnant women to SHS. These will be conducted in peri-urban slums and rural settings of Rawalpindi district with expectant or new father who smoke and pregnant or new mothers exposed to SHS. Interview guide will be developed deductively as a result of the systematic review and will be piloted before its actual use. Trained interviewer will conduct in-depth interview using semi-structured interview guide and will record it with consent from respondents. This data will be transcribed and translated and coded by team of two researchers.
Study NCT02738775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Administered as an IV infusion.
Study NCT02738775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03259867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injectable Product
Description: a PD-1 immune check inhibitor
Study NCT02683759 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bio-enhanced Curcumin Soft Gelatin Capsule
Description: Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)~Starting dose: 50 mg BID of Bioenhanced Curcumin Increase dose to 100 mg BID after two (2) weeks if there is no response to the drug
Study NCT02683759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Aminosalicyclic acid
Description: Dosage is as instructed by patient's physician
Study NCT02683759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Aminosalicyclic acid
Description: Dosage is as instructed by patient's physician
Study NCT02992899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GammaCore/electroCore non-invasive VNS device
Description: Vasal nerve stimulation (VNS) is self-administered using the electroCore non-invasive VNS device. The intensity of the stimulus (the current amplitude) is adjusted by the user, to the maximum tolerable level to ensure VNS without causing excessive pain (typically 10-30 V), the burst frequency to 5 kilohertz (kHz), and the envelope frequency to 25 Hz. These are the standard frequency settings that electroCore has demonstrated to be most effective in capturing the vagus nerve based on evoked potential studies. The duration of delivery is 2 minutes, one minute into which the high-resolution positron emission tomography (HR-PET) scan is conducted; following an additional 8 minutes, a second VNS delivery is administered, after which another scan is obtained.
Study NCT02992899 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham gammaCore/electroCore
Description: Sham vasal nerve stimulation (VNS) is self-administered using the electroCore non-invasive VNS device. The device is programmed such that no actual stimulation is given to the vagus nerve. The duration of delivery is 2 minutes, one minute into which the HR-PET scan is conducted; following an additional 8 minutes, a second sham VNS delivery is administered, after which another scan is obtained.